Reslizumab in Patients With Corticosteroid Dependent Asthma and Elevated Eosinophils
- Study Title
- An Efficacy and Safety Study of Reslizumab Subcutaneous in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood Eosinophils
- Teva Identifier
- C38072-AS-30027 | 2015-001580-39
- ClinicalTrials.gov Identifier
- NCT02501629
- Study Status
- Completed
- Trial Condition(s)
- Asthma | Elevated Blood Eosinophils | Oral Corticosteroid Dependence
- Interventions
- Drug: Reslizumab | Drug: Placebo | Drug: Non-Oral Corticosteroid (non-OCS) Asthma Medication | Drug: Oral Corticosteroid (OCS)
- Study Description
- Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
- Gender
- Female, Male
- Age group
- Child, Adult, Older Adult
- Age Range
- 12 Years and older
- Trial Duration
- September 29, 2015 - December 4, 2017
- Phase
- Phase 3